GeneralTop StoryTop StoryLatest News
Zomato's Deepinder Goyal Defends Temple Device, Says It's Not for Indians
Sentiment: NeutralHigh Priority
What Happened?
Deepinder Goyal, founder of Zomato, has defended his health-tech product, Temple, stating it is aimed at global markets and not specifically for India. The device, priced at Rs 85,000, is currently available for pre-order.
Key points
- Temple is priced at Rs 85,000 and aims for global sales.
- Goyal stated that Temple is not a medical device and does not diagnose diseases.
- The device's main feature is called Entropy, not BrainFlow.
- Critics, including doctors, have questioned the scientific validity of Temple.
- Goyal encourages potential buyers to wait for peer-reviewed research before purchasing.
Key insights
- Temple's pricing strategy may limit its adoption in India.
- The focus on global markets suggests a shift in consumer tech trends.
- Criticism from medical professionals could impact Temple's credibility.
Why it matters
The launch of Temple could influence the wearable tech market, particularly in health and fitness.
Entities
Deepinder Goyal· PersonZomato· CompanyTemple· ProductIndia· Country
Source
India Today
